Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Refractoriness to ruxolitinib in patients with myelofibrosis (MF) was associated with clonal evolution; however, whether genetic instability is promoted by ruxolitinib remains unsettled. We evaluated the mutation landscape in 71 MF patients receiving ruxolitinib (n = 46) and hydroxyurea (n = 25) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacilli, Annalisa, Rotunno, Giada, Mannarelli, Carmela, Fanelli, Tiziana, Pancrazzi, Alessandro, Contini, Elisa, Mannelli, Francesco, Gesullo, Francesca, Bartalucci, Niccolò, Fattori, Giuditta Corbizi, Paoli, Chiara, Vannucchi, Alessandro M., Guglielmelli, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250726/
https://www.ncbi.nlm.nih.gov/pubmed/30467377
http://dx.doi.org/10.1038/s41408-018-0152-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250726/
https://www.ncbi.nlm.nih.gov/pubmed/30467377
http://dx.doi.org/10.1038/s41408-018-0152-x

Ejemplares similares